Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b_20260413-202651",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"FcγRIIB Upregulation Failure Permits Anti-AQP4 B Cell Escape\",\n      \"mechanism\": \"AQP4-specific B cells in healthy individuals upregulate inhibitory FcγRIIB (CD32) upon chronic AQP4 engagement, recruiting SHP-1 to attenuate BCR signaling; NMO patients exhibit impaired FcγRIIB upregulation due to defective BTK/CARD11 signaling.\",\n      \"target_gene\": \"FCGR2B\",\n      \"confidence_score\": 0.65,\n      \"novelty_score\": 0.55,\n      \"feasibility_score\": 0.60,\n      \"impact_score\": 0.85,\n      \"composite_score\": 0.67,\n      \"testable_prediction\": \"Compare FcγRIIB expression and SHP-1 recruitment in AQP4-specific B cells from NMO patients vs. healthy controls upon BCR stimulation in vitro.\",\n      \"skeptic_concern\": \"AQP4 is CNS-restricted with minimal systemic access, challenging the premise of chronic peripheral AQP4 engagement required for FcγRIIB upregulation.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Regulatory B Cell (Breg) IL-10 Production Suppresses Anti-AQP4 Responses\",\n      \"mechanism\": \"IL-10-producing Bregs in healthy individuals actively suppress AQP4-specific B cell activation and plasma cell differentiation through PD-L1 and IL-10 secretion; NMO patients have reduced Breg frequency or functional impairment.\",\n      \"target_gene\": \"IL10\",\n      \"confidence_score\": 0.60,\n      \"novelty_score\": 0.70,\n      \"feasibility_score\": 0.65,\n      \"impact_score\": 0.75,\n      \"composite_score\": 0.67,\n      \"testable_prediction\": \"Quantify IL-10+ Breg frequency and suppressive function in NMO patients vs. healthy controls and test whether IL-10 receptor blockade breaks tolerance in vitro.\",\n      \"skeptic_concern\": \"Whether Bregs preferentially target AQP4-specific B cells among diverse autoreactive specificities remains unclear.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Anergic B Cell Receptor Desensitization Maintains Anti-AQP4 Tolerance\",\n      \"mechanism\": \"AQP4-specific B cells undergo anergy induction through chronic low-affinity self-antigen exposure, resulting in reduced BCR signaling responsiveness and elevated SHP-1 expression; NMO patients fail to establish or maintain this anergic state.\",\n      \"target_gene\": \"PTPN6 (SHP-1)\",\n      \"confidence_score\": 0.55,\n      \"novelty_score\": 0.60,\n      \"feasibility_score\": 0.70,\n      \"impact_score\": 0.70,\n      \"composite_score\": 0.62,\n      \"testable_prediction\": \"Measure BCR calcium flux and SHP-1 expression in AQP4-specific B cells sorted from healthy donors vs. NMO patients to assess anergy markers.\",\n      \"skeptic_concern\": \"Anergy mechanisms typically require continuous antigen exposure, raising the same systemic AQP4 access concern as Hypothesis 1.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"B cell tolerance to AQP4 is actively maintained rather than passively absent in healthy individuals\",\n    \"NMO patients exhibit measurable defects in B cell tolerance mechanisms\",\n    \"FcγRIIB signaling pathway is a credible therapeutic target for restoring tolerance\"\n  ],\n  \"dissent_points\": [\n    \"Whether AQP4 or AQP4 fragments reach peripheral lymphoid organs in sufficient quantities to drive tolerance mechanisms remains mechanistically unexplained\",\n    \"Whether the primary defect is B cell-intrinsic (FcγRIIB dysregulation) vs. B cell-extrinsic (T cell help, regulatory mechanisms) is unresolved\"\n  ],\n  \"debate_summary\": \"Theorist proposes FcγRIIB dysregulation as the primary tolerance mechanism, supported by established autoimmunity models but challenged by the skeptic's valid concern that CNS-restricted AQP4 cannot drive peripheral B cell tolerance. The expert prioritizes this hypothesis for translational potential despite the antigen access gap. Alternative tolerance mechanisms (Breg-mediated suppression, anergy) offer complementary or compensatory pathways that may resolve the antigen access paradox while maintaining therapeutic relevance.\"\n}",
  "tokens_used": "984"
}